AR109729A1 - Método para producir la forma cristalina de modificación a de calcobutrol - Google Patents
Método para producir la forma cristalina de modificación a de calcobutrolInfo
- Publication number
- AR109729A1 AR109729A1 ARP170102671A ARP170102671A AR109729A1 AR 109729 A1 AR109729 A1 AR 109729A1 AR P170102671 A ARP170102671 A AR P170102671A AR P170102671 A ARP170102671 A AR P170102671A AR 109729 A1 AR109729 A1 AR 109729A1
- Authority
- AR
- Argentina
- Prior art keywords
- modification
- calcolutrol
- producing
- crystal form
- high purity
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title abstract 3
- 238000012986 modification Methods 0.000 title abstract 3
- 230000004048 modification Effects 0.000 title abstract 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- ZPDFIIGFYAHNSK-CTHHTMFSSA-K 2-[4,10-bis(carboxylatomethyl)-7-[(2r,3s)-1,3,4-trihydroxybutan-2-yl]-1,4,7,10-tetrazacyclododec-1-yl]acetate;gadolinium(3+) Chemical compound [Gd+3].OC[C@@H](O)[C@@H](CO)N1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1 ZPDFIIGFYAHNSK-CTHHTMFSSA-K 0.000 abstract 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
- 229910052688 Gadolinium Inorganic materials 0.000 abstract 1
- 229910052791 calcium Inorganic materials 0.000 abstract 1
- 239000011575 calcium Substances 0.000 abstract 1
- 159000000007 calcium salts Chemical class 0.000 abstract 1
- 238000002425 crystallisation Methods 0.000 abstract 1
- 230000008025 crystallization Effects 0.000 abstract 1
- ZPDFIIGFYAHNSK-UHFFFAOYSA-K gadobutrol Chemical compound [Gd+3].OCC(O)C(CO)N1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1 ZPDFIIGFYAHNSK-UHFFFAOYSA-K 0.000 abstract 1
- 229960003411 gadobutrol Drugs 0.000 abstract 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 235000006408 oxalic acid Nutrition 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
- C07F3/04—Calcium compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
- A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
- A61K49/108—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA the metal complex being Gd-DOTA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Radiology & Medical Imaging (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Saccharide Compounds (AREA)
Abstract
Se describe un método para la producción de un compuesto con pureza elevada de la fórmula (1) en forma cristalina de la modificación A. En esto, comenzando a partir de gadobutrol de elevada pureza, se elimina el gadolinio por descomplejación con ácido oxálico, y luego con una sal cálcica se produce el complejo cálcico con pureza elevada. Durante la cristalización, se establece un equivalente de agua del 9 - 11% en peso. Se emplea la forma cristalina de la modificación A del compuesto de la fórmula (1) en la producción de Gadovist.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16190812 | 2016-09-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR109729A1 true AR109729A1 (es) | 2019-01-16 |
Family
ID=57003447
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170102671A AR109729A1 (es) | 2016-09-27 | 2017-09-27 | Método para producir la forma cristalina de modificación a de calcobutrol |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US10793532B2 (es) |
| EP (1) | EP3519394B1 (es) |
| JP (2) | JP7053590B2 (es) |
| KR (1) | KR102395523B1 (es) |
| CN (1) | CN109803958B (es) |
| AR (1) | AR109729A1 (es) |
| AU (1) | AU2017333698B2 (es) |
| BR (1) | BR112019006066A2 (es) |
| CA (1) | CA3038036C (es) |
| CY (1) | CY1123317T1 (es) |
| DK (1) | DK3519394T3 (es) |
| ES (1) | ES2809736T3 (es) |
| HR (1) | HRP20200922T1 (es) |
| HU (1) | HUE050553T2 (es) |
| IL (1) | IL265536B (es) |
| LT (1) | LT3519394T (es) |
| MX (1) | MX382574B (es) |
| NZ (1) | NZ751256A (es) |
| PL (1) | PL3519394T3 (es) |
| PT (1) | PT3519394T (es) |
| RS (1) | RS60392B1 (es) |
| SG (1) | SG11201901460UA (es) |
| SI (1) | SI3519394T1 (es) |
| TW (1) | TWI765913B (es) |
| UY (1) | UY37421A (es) |
| WO (1) | WO2018059914A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS60392B1 (sr) * | 2016-09-27 | 2020-07-31 | Bayer Pharma AG | Postupak za proizvodnju kristalnog oblika modifikacije a kalkobutrola |
| EP4083026A1 (en) * | 2018-07-10 | 2022-11-02 | Biophore India Pharmaceuticals Pvt. Ltd. | Process for the preparation of 2,2',2''-(10-((2r,3s)-1,3,4-trihydroxy butan-2-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl) triacetic acid and its complexes |
| WO2020084504A1 (en) * | 2018-10-24 | 2020-04-30 | Biophore India Pharmaceuticals Pvt. Ltd | Novel process for the preparation of macrocyclic chelant 2,2',2''-(10-(2-hydroxypropyl)-1,4,7,10-tetra azacyclododecane-1,4,7-triyl) triacetic acid and it's complexes with paramagnetic metal ions |
| CN111039885B (zh) * | 2019-12-06 | 2021-03-05 | 广州康瑞泰药业有限公司 | 一种制备高纯度考布曲钙的方法 |
| KR20210112910A (ko) * | 2020-03-06 | 2021-09-15 | 주식회사 엔지켐생명과학 | 가도부트롤 주사제 제조를 위한 부형제인 칼코부트롤의 제조 방법 |
| KR20210114742A (ko) * | 2020-03-11 | 2021-09-24 | 주식회사 엔지켐생명과학 | 칼테리돌의 제조방법 |
| CN114573522A (zh) * | 2020-11-30 | 2022-06-03 | 江苏恒瑞医药股份有限公司 | 一种考布曲钙的新晶型及其制备方法 |
| CN119143689B (zh) * | 2024-11-15 | 2025-05-30 | 苏州美诺医药科技有限公司 | 考布曲钙和其中间体的制备方法 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1491129A (en) | 1975-06-04 | 1977-11-09 | Guerbet Sa | Iodo-benzene derivatives and an x-ray contrast medium containing them |
| US4284620A (en) | 1979-03-23 | 1981-08-18 | Mallinckrodt, Inc. | N-(2-Hydroxyethyl)-2,4,6-triiodo-3,5-bis-(2-keto-L-gulonamido)benzamide and radiological compositions containing same |
| NO161560C (no) | 1980-04-17 | 1989-09-06 | Univ California | Symmetriske trijodisoftaldiamid-derivater og roentgenkontrastmidler inneholdende disse. |
| DE3150916A1 (de) | 1981-12-18 | 1983-06-30 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | N-hydroxyaethylierte 2,4,6-trijodaminoisiophthalsaeure-bis- trihydroxybutylamide, deren herstellung und diese enthaltende roentgenkontrastmittel" |
| US5064633A (en) | 1984-06-04 | 1991-11-12 | The Dow Chemical Company | Macrocyclic aminophosphonic acid complexes, their formulations and use |
| US5059412A (en) | 1984-06-04 | 1991-10-22 | The Dow Chemical Company | Macrocyclic aminophosphonic acid complexes for the treatment of calcific tumors |
| US4885363A (en) | 1987-04-24 | 1989-12-05 | E. R. Squibb & Sons, Inc. | 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs |
| MX174467B (es) | 1986-01-23 | 1994-05-17 | Squibb & Sons Inc | 1,4,7-triscarboximetil-1,4,7,10-tetraazaciclodo decano substituido en 1 y compuestos analogos |
| DE3625417C2 (de) | 1986-07-28 | 1998-10-08 | Schering Ag | Tetraazacyclododecan-Derivate |
| DE3640708C2 (de) | 1986-11-28 | 1995-05-18 | Schering Ag | Verbesserte metallhaltige Pharmazeutika |
| DE4009119A1 (de) | 1990-03-19 | 1991-09-26 | Schering Ag | 1,4,7,10-tetraazacyclododecan-butyltriole, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel |
| IE910955A1 (en) | 1990-03-23 | 1991-09-25 | Yamanouchi Europ Bv | Il-6 inhibiting compositions |
| DE4035760A1 (de) | 1990-11-08 | 1992-05-14 | Schering Ag | Mono-n-substituierte 1,4,7,10-tetraazacyclododecan-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel |
| DE4237943C2 (de) | 1992-11-06 | 1997-10-23 | Schering Ag | Verfahren zur Herstellung von Metallkomplexen der N-beta-Hydroxyalkyl-tri-N-carboxyalkyl-1,4,7,10-tetraazacyclododecan- und N-beta-Hydroxyalkyl-tri-N-carboxyalkyl-1,4,8,11-tetraazacyclotetradecan-Derivate |
| US5410043A (en) | 1991-12-06 | 1995-04-25 | Schering Aktiengesellschaft | Process for the production of mono-N-substituted tetraaza macrocycles |
| DE4218744C2 (de) | 1992-06-04 | 1997-11-06 | Schering Ag | Verfahren zur Herstellung von N-ß-Hxdroxyalkyl-tri-N-carboxylalkyl-1,4,7,10-tetraazacyclododecan- und N-ß-Hydroxyalkyl-tri-N-carboxyalkyl-1,4,8,11-tetraazacyclotetradecan-Derivaten und deren Metallkomplexe |
| DE4318369C1 (de) | 1993-05-28 | 1995-02-09 | Schering Ag | Verwendung von makrocyclischen Metallkomplexen als Temperatursonden |
| US5358704A (en) | 1993-09-30 | 1994-10-25 | Bristol-Myers Squibb | Hepatobiliary tetraazamacrocyclic magnetic resonance contrast agents |
| IT1275426B (it) | 1995-05-16 | 1997-08-07 | Bracco Spa | Recupero del gadolinio e dei suoi agenti complessanti da soluzioni acquose contenenti i loro complessi |
| DE19724186C2 (de) | 1997-06-02 | 2002-07-18 | Schering Ag | Verfahren zur Mono- und 1,7-Bis-N-ß-Hydroxyalkylierung von Cyclen und die entsprechenden N-ß-Hydroxyalkyl-1,4,7,10-tetraazacyclododecan-Li-Salz-Komplexe |
| US9016221B2 (en) | 2004-02-17 | 2015-04-28 | University Of Florida Research Foundation, Inc. | Surface topographies for non-toxic bioadhesion control |
| DE102009053171B4 (de) * | 2009-11-04 | 2011-07-21 | Bayer Schering Pharma Aktiengesellschaft, 13353 | Verfahren zur Herstellung des Calcium-Komplexes von Dihydroxy-hydroxy-methylpropyl-tetraazacyclododecan-triessigsäure (Calcobutrol) |
| JP6096757B2 (ja) * | 2011-04-21 | 2017-03-15 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | 高純度ガドブトロールの製造 |
| EP2717860A4 (en) * | 2011-06-08 | 2014-11-05 | Sti Pharma Llc | FORMULATION FROM A WATER SOLUBLE AND PHARMACEUTICALLY ACTIVE ORGANIC COMPOUND WITH CONTROLLED ABSORPTION FOR ONLY DAILY APPLICATION |
| KR101693400B1 (ko) | 2014-09-17 | 2017-01-05 | 에스티팜 주식회사 | 칼코부트롤의 제조방법 |
| CN105037288B (zh) * | 2015-07-23 | 2017-11-03 | 上海现代制药海门有限公司 | 一种布醇的制备方法 |
| CN106187930B (zh) * | 2016-07-12 | 2018-10-19 | 嘉实（湖南）医药科技有限公司 | 高纯度考布曲钙的制备方法 |
| RS60392B1 (sr) * | 2016-09-27 | 2020-07-31 | Bayer Pharma AG | Postupak za proizvodnju kristalnog oblika modifikacije a kalkobutrola |
-
2017
- 2017-09-11 RS RS20200654A patent/RS60392B1/sr unknown
- 2017-09-11 CN CN201780058632.5A patent/CN109803958B/zh active Active
- 2017-09-11 WO PCT/EP2017/072683 patent/WO2018059914A1/en not_active Ceased
- 2017-09-11 ES ES17768733T patent/ES2809736T3/es active Active
- 2017-09-11 IL IL265536A patent/IL265536B/en unknown
- 2017-09-11 SI SI201730298T patent/SI3519394T1/sl unknown
- 2017-09-11 HR HRP20200922TT patent/HRP20200922T1/hr unknown
- 2017-09-11 LT LTEP17768733.2T patent/LT3519394T/lt unknown
- 2017-09-11 US US16/336,217 patent/US10793532B2/en active Active
- 2017-09-11 BR BR112019006066A patent/BR112019006066A2/pt not_active Application Discontinuation
- 2017-09-11 HU HUE17768733A patent/HUE050553T2/hu unknown
- 2017-09-11 PT PT177687332T patent/PT3519394T/pt unknown
- 2017-09-11 CA CA3038036A patent/CA3038036C/en active Active
- 2017-09-11 DK DK17768733.2T patent/DK3519394T3/da active
- 2017-09-11 KR KR1020197008763A patent/KR102395523B1/ko active Active
- 2017-09-11 AU AU2017333698A patent/AU2017333698B2/en active Active
- 2017-09-11 JP JP2019516489A patent/JP7053590B2/ja active Active
- 2017-09-11 NZ NZ751256A patent/NZ751256A/en unknown
- 2017-09-11 SG SG11201901460UA patent/SG11201901460UA/en unknown
- 2017-09-11 MX MX2019003540A patent/MX382574B/es unknown
- 2017-09-11 PL PL17768733T patent/PL3519394T3/pl unknown
- 2017-09-11 EP EP17768733.2A patent/EP3519394B1/en active Active
- 2017-09-27 TW TW106133043A patent/TWI765913B/zh active
- 2017-09-27 AR ARP170102671A patent/AR109729A1/es unknown
- 2017-09-27 UY UY0001037421A patent/UY37421A/es unknown
-
2020
- 2020-07-30 CY CY20201100709T patent/CY1123317T1/el unknown
- 2020-09-22 US US17/028,467 patent/US11390592B2/en active Active
-
2022
- 2022-03-03 JP JP2022032582A patent/JP7444914B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR109729A1 (es) | Método para producir la forma cristalina de modificación a de calcobutrol | |
| ES2660773T3 (es) | Procedimiento para la preparación de una sal cristalina trialcalino-metálica de L-MGDA | |
| AR066130A1 (es) | Formas cristalinas de saxagliptina y procesos para preparar las mismas | |
| EA201200652A1 (ru) | Способ получения кальцобутрола | |
| PH12016502334A1 (en) | Method for producing fused heterocyclic compound | |
| AR133154A2 (es) | Proceso de producción de cristales de derivado de diazabiciclooctano y preparación liofilizada estable | |
| CR20150663A (es) | Derivados de diazacarbazol como ligandos de tau para pet | |
| MX2022015151A (es) | Procesos para preparar acido 3-(3-(3,5-dimetil-1h-pirazol-4-il)pro poxi)-4- 5-fluorobenzoico (ag-10), sus compuestos intermedios, y sales del mismo. | |
| PE20140636A1 (es) | Conjugado de naloxol-peg cristalino | |
| NZ601805A (en) | Method for preparing tetrazole methanesulfonic acid salts, and novel compound used in same | |
| NZ718607A (en) | Synthetic route to 2’-deoxy-2’,2’-difluorotetrahydrouridines | |
| RU2016148241A (ru) | Синтез комплекса цинка с лизином из хлорида цинка | |
| CO6241155A2 (es) | [4-(6-fluoro-7-metilamina-2,4-dioxo-1,4-dihidro-2hquinazolina-3-ilo)-fenilo]-5-cloro-tiofeno-2-ilo-sales de sulfonilurea y las formas y metodos relacionados con el mismo | |
| PE20140337A1 (es) | Nuevas formas cristalinas de la sal sodica del acido (4-{4-[5-(6-trifluoro-metil-piridin-3-il-amino)-piridin-2-il]-fenil}-ciclhexil)-acetico | |
| AR081267A1 (es) | Procedimiento de obtencion de la forma cristalina a del febuxostat | |
| MX2017006298A (es) | Proceso para producir acido acetico introduciendo un compuesto de litio. | |
| CL2012000270A1 (es) | Procedimiento de preparacion de ivabradina y de sus sales de adicion por formacion del anillo benzoacepino; y los compuestos intermediarios considerados en el procedimiento. | |
| MX2017014319A (es) | Sal sodica de inhibidor de transportador de acido urico y su forma cristalina. | |
| ES2523346T3 (es) | Un proceso para preparar sal de tricloroaminoplatinato y los productos obtenidos en el mismo | |
| AR101487A1 (es) | Formas cristalinas de un modulador de receptor de estrógeno | |
| WO2015022702A3 (en) | Process for preparation of 4,5-dimethoxybenzene derivatives and use in the synthesis of ivabradine and salts thereof | |
| BR112021020864A2 (pt) | Formas cristalinas e métodos de produção de formas cristalinas de um composto | |
| CL2012001528A1 (es) | Proceso para preparar la forma cristalina a de ilaprazol a partir de una sal inorganica de ilaprazol y posterior neutralizacion de la sal con un acido en un solvente de reaccion; y proceso para preparar la forma cristalina b de ilaprazol en la forma cristalina a de ilaprazol. | |
| JO3276B1 (ar) | طريقة لتخليق 3، 4-داي ميثوكسي باي سيكلو [4. 2. 0] أوكتا-5،3،1-تراي إين-7-كربونيتريل واستخدامها لتخليق ايفابرادين والأملاح المضافة منه مع حمض مقبول صيدلانيا. | |
| AR068349A1 (es) | Polimorfos de agonistas de prostaglandinas y procedimientos para fabricar los mismos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |